Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Assetmark Inc.

Assetmark Inc. lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 84.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 305 shares of the medical research company’s stock after acquiring an additional 140 shares during the period. Assetmark Inc.’s holdings in Bio-Rad Laboratories were worth $102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. UMB Bank n.a. boosted its stake in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Capital Advisors Ltd. LLC boosted its stake in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Bio-Rad Laboratories during the first quarter worth $51,000. Headlands Technologies LLC acquired a new position in Bio-Rad Laboratories during the second quarter worth $51,000. Finally, Quarry LP acquired a new position in Bio-Rad Laboratories during the second quarter worth $59,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bio-Rad Laboratories

In related news, EVP James Barry sold 623 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 80.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The trade was a 28.41 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Stock Down 8.5 %

Shares of NYSE BIO opened at $320.31 on Monday. The stock has a market cap of $8.97 billion, a PE ratio of -11.72 and a beta of 0.93. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99. The business has a 50-day moving average price of $340.48 and a 200 day moving average price of $314.67.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. During the same period last year, the firm earned $2.33 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Royal Bank of Canada upped their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $391.80.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.